You are here

More People Can Receive Smallpox Vaccine in an Emergency

The U.S. government currently stockpiles enough traditional smallpox vaccine to protect the entire American population in the event of a smallpox bioterrorism attack. However, these replicating vaccines may cause severe complications for people with compromised immune systems or AD. Imvamune is being developed as an alternative for these individuals.

In its 2010 Broad Agency Announcement for Medical Countermeasure Development, the Biomedical Advanced Research and Development Authority (BARDA) noted the need for a sufficient quantity of attenuated smallpox vaccine to protect 28 million people with AD, 10 million people with compromised immune systems, and their household contacts––totaling 66 million people.

To date, the government has ordered 20 million doses of Imvamune to protect the 10 million people with immune deficiencies, in particular HIV infection. Bavarian Nordic expects to complete delivery of these vaccine doses by 2013.

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications